AN INTERNATIONAL OBSERVATIONAL STUDY TO ASSESS THE USE OF SORAFENIB AFTER TRANSARTERIAL CHEMOEMBOLIZATION (TACE) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC): OPTIMIS

被引:1
|
作者
Peck-Radosavljevic, M. [1 ]
Raoul, J. -L. [2 ]
Lee, H. C. [3 ]
Kudo, M. [4 ]
Nakajima, K. [5 ]
Cheng, A. -L. [6 ]
机构
[1] Inst J Paoli I Calmettes, F-13009 Marseille, France
[2] Med Univ Vienna, Vienna, Austria
[3] Asan Med Ctr, Seoul, South Korea
[4] Kinki Univ, Sch Med, Osaka 589, Japan
[5] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[6] Natl Taiwan Univ Hosp, Taipei, Taiwan
关键词
D O I
10.1016/S0168-8278(15)31517-8
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
P1338
引用
收藏
页码:S858 / S858
页数:1
相关论文
共 50 条
  • [41] TRANSARTERIAL CHEMOEMBOLIZATION OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) WITH DRUG ELUTING BEADS (DEB-TACE)
    Campo, N.
    Gazzo, P.
    Azzola, E.
    Lupo, S.
    Ivaldi, D.
    Barbera, G.
    Magnolia, M.
    Milazzo, S.
    Rainisio, C.
    Testa, R.
    DIGESTIVE AND LIVER DISEASE, 2010, 42 : S153 - S153
  • [42] Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease
    Kirstein, Martha M.
    Voigtlaender, Torsten
    Schweitzer, Nora
    Hinrichs, Jan B.
    Marquardt, Jens
    Woerns, Marcus-Alexander
    Kloeckner, Roman
    Fruendt, Thorben W.
    Ittrich, Harald
    Wacker, Frank
    Rodt, Thomas
    Manns, Michael P.
    Wege, Henning
    Weinmann, Arndt
    Vogel, Arndt
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2018, 6 (02) : 238 - 246
  • [43] Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma
    Park, Joong-Won
    Koh, Young Hwan
    Kim, Hyun Beom
    Kim, Hwi Young
    An, Sangbu
    Choi, Joon-Il
    Woo, Sang Myung
    Nam, Byung-Ho
    JOURNAL OF HEPATOLOGY, 2012, 56 (06) : 1336 - 1342
  • [44] Efficacy of apatinib in patients with sorafenib–transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study
    Yanyan Cao
    Tao Ouyang
    Fu Xiong
    Xuefeng Kan
    Lei Chen
    Bin Liang
    Chuansheng Zheng
    Hepatology International, 2021, 15 : 1268 - 1277
  • [45] Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma
    Ha, Yeonjung
    Lee, Danbi
    Shim, Ju Hyun
    Lim, Young-Suk
    Lee, Han Chu
    Chung, Young-Hwa
    Lee, Yung Sang
    Park, Sook Ryun
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Kang, Yoon-Koo
    Kim, Kang Mo
    ONCOTARGET, 2016, 7 (45) : 74303 - 74313
  • [46] Effects of Oral L-Carnitine on Liver Functions After Transarterial Chemoembolization (TACE) in Intermediate Stage Hepatocellular Carcinoma (HCC) Patients
    Hassan, Abeer A.
    Tsuda, Yasuhiro
    Asai, Akira
    Yokohama, Keisuke
    Ohama, Hideko
    Nakamura, Ken
    Sujishi, Tetsuya
    Tsuchimoto, Yusuke
    Fukunishi, Shinya
    Malak, Mohamed M.
    Arafa, Usama A.
    Hassan, Ali T.
    Kassem, Ali
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2015, 148 (04) : S1021 - S1021
  • [47] SINGLE CENTRE EXPERIENCE OF USE OF TRANSARTERIAL CHEMOEMBOLIZATION (TACE) WITH DOXORUBICIN ELUTING BEADS (DEB) FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC)
    Jamil, K.
    Fotiadis, N.
    Lowe, D.
    Kooner, P.
    GUT, 2011, 60
  • [48] Transarterial chemoembolization (TACE) combined with Sorafenib is more effective than TACE for hepatocellular carcinoma with portal vein tumor thrombus
    Zhang, Ze-Han
    Zhu, Hui-Min
    Zhou, Teng-Fei
    Li, Nan
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S544 - S546
  • [49] Tumoral and angiogenesis factors in hepatocellular carcinoma (HCC) after drug eluting bead (DEB) transarterial chemoembolization (TACE) with doxorubicin
    Farris, A. B.
    Dhanasekaran, R.
    Dursun, N.
    Coban, I.
    McIntosh, E. B.
    Adsay, V.
    Kim, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis
    Zhang, Leida
    Hu, Peng
    Chen, Xi
    Bie, Ping
    PLOS ONE, 2014, 9 (06):